Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Nuance Announces $213 Million Deal for China Rights to Inhaled RDS Therapy

publication date: Dec 23, 2021

Shanghai Nuance Pharma acquired China rights to AeroFact™, an innovative non-invasive therapy for respiratory distress syndrome developed by Ireland's Aerogen, in a $213 million deal. AeroFact uses Aerogen's vibrating mesh nebulizer aerosolization technology to deliver a pulmonary surfactant drug. RDS, a life-threatening condition for preterm infants, causes long-term lung health issues in survivors. Aerogen Pharma will receive a $20 million upfront payment and $10 million equity in Nuance, plus $182.5 million in milestone payments. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital